Grrrr, I lost another post when I accidentally activated a different browser mode
Bad luck biophile!
I think we should organise some sort of forum consolation prize, for when people lose a post or private message!
It might make it slightly less distressing!
I was initially impressed by the "Lipkin study", but have since become concerned about the patient cohort, largely because of rlc's detailed comments on another thread about how sparse the tests were to exclude other diseases. Also because there was no obvious emphasis on post-exertion symptom exacerbation or relapse (as opposed to vague post-exertional fatigue which will meet the minimum linguistic requirement in the CCC).
The only major issue I can see with Lipkin's cohort is if the selection criteria accidentally excluded all ME patients, and only included patients with some other unknown illness. But I don't think this can be the case. I think it would only have ruled out a subset of CFS/ME patients.
I agree that Lipkin's cohort isn't perfect, and it's a shame that they didn't set about excluding alternative diagnoses, or at least make some effort towards it. There have been at least a couple of papers over the past couple of years that demonstrated that a high proportion of ME diagnoses are incorrect.
But the patients came from well established clinicians, such as Peterson and Klimas, so hopefully they know what they are doing, more than a normal family doctor would do. So there would have been an 'ME' diagnosis from a well established physician.
An ME cohort can never be perfect until we understand the cause, and there are always going to be issues with cohorts. Lipkin's cohort is much better than many CFS cohorts that have been used in other research, because Lipkin selected patients with a viral-type onset, with some physical signs of illness. So this ruled out ideopathic fatigue, at least. This seems better than the alternative of a loosely defined CFS cohort.
Lipkin has stated that he is interested in establishing subsets, and that he is not expecting his cohort to be a single discrete disease. So, he's aware of the difficulties.
Some people have said that the cohort could be the reason that no viruses were detected.
But this can't be the case, because roughly 5% positives would still have been detected in the control group, if that was the case.
As for the virology, I have not had a chance to have a closer look at the paper, but AFAIK the authors had freedom with their methods to detect XMRV/pMLV. I am also vaguely aware of allusions that the entire study was rigged to debunk the previous findings, and Mikovits cannot speak out because she signed what amounts to a gag order or whatever.
Yes, Mikovits used her own methodology, at least after the blood collection/processing/storage stage.
And from the accounts that I've read, she played a major role in designing the blood collection/processing/storage methodology, and agreed to the methodology before the study went ahead.
Lipkin wouldn't have gone ahead with it until all the researchers were signed up to the methodology. And my interpretation is that Lipkin went out of his way to accommodate Mikovit's needs and criteria.
So the only way I can see the study was flawed, is if either Mikovits didn't know what she was doing, or if the samples were purposely tampered with. Neither of which is worth devoting any mental energy to, in my opinion.
As for "next generation sequencing", this is a general term for a range of much faster techniques with high-throughput due to parallelization, allowing for more to be done. However, NGS is not necessarily more accurate than the previous gold standard, so "deep sequencing" (repetition) is used to improve the accuracy. As I understand it, although the recent XMRV/pMLV study did not use NGS (the primary purpose of which was to investigate the associations made in the previous two papers on XMRV and pMLV), there are other projects underway which do use NGS and perhaps should find anything which was not found in the recent study due to a much broader search?
One other reason for NGS, is to find out if a virus is integrated into the human genome.
But, as Lipkin said, the purpose of this study was only to replicate the original study, and not to go further.
Lipkin says that if retroviruses are there, then he would hope they would show up in his pathogen studies.
He is carrying out NGS on RNA and DNA, and is also looking at proteins.
I've read that he is investigating faeces, tears, saliva, blood, and spinal fluid.
So his ongoing research seems to be a very powerful investigation.